GNH USA

Europe — EMA

Irsamla (Vortioxetine Hydrobromide)

GNH USA supplies Irsamla (Vortioxetine), a serotonin modulator and stimulator for major depressive disorder. Request a quote for global supply.

Vortioxetine Hydrobromide

Request sourcing

1
Pack/s

What is Vortioxetine Hydrobromide?

Vortioxetine Hydrobromide, the active ingredient in Irsamla, is a serotonin modulator and stimulator presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adults.

GNH USA supplies Irsamla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Vortioxetine Hydrobromide used for?

Irsamla (vortioxetine) acts on serotonergic pathways to alleviate depressive symptoms.

Major Depressive Disorder: reduces depressive symptoms and improves functional outcomes in adult patients.

What are the side effects of Vortioxetine Hydrobromide?

Vortioxetine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea - Headache - Dizziness - Dry mouth - Constipation - Insomnia

Serious or Rare Side Effects: - Serotonin syndrome - Suicidal thoughts or behavior - Severe hyponatremia - Allergic reactions (rash, angioedema) - QT interval prolongation

What precautions apply to Vortioxetine Hydrobromide?

When prescribing Irsamla, clinicians should consider several safety measures. - Suicidal risk assessment: monitor patients for emergent suicidal thoughts, especially early in therapy. - Serotonin syndrome: avoid concurrent use of other serotonergic agents. - Hepatic impairment: dose adjustment may be required in moderate to severe liver disease. - Discontinuation: taper gradually to reduce withdrawal symptoms. - MAO inhibitor use: ensure a minimum 14‑day washout period before initiating vortioxetine. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

What does Vortioxetine Hydrobromide interact with?

Vortioxetine can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - Linezolid or other reversible MAO‑A inhibitors. - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): may increase vortioxetine exposure.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., tamoxifen): possible altered efficacy. - NSAIDs or anticoagulants: increased bleeding risk. - Alcohol: may exacerbate central nervous system effects. - Antihistamines with serotonergic activity: monitor for additive side effects.

Frequently asked questions

What is Irsamla used for?+
Irsamla contains vortioxetine, an antidepressant indicated for the treatment of major depressive disorder in adult patients. It works by enhancing serotonergic neurotransmission to improve mood and functional outcomes.
How does vortioxetine work?+
Vortioxetine modulates several serotonin receptors—acting as an agonist at 5‑HT1A, a partial agonist at 5‑HT1B, and an antagonist at 5‑HT3 and 5‑HT7—while inhibiting the serotonin transporter. This multifaceted activity increases serotonin signaling in brain circuits that regulate mood.
What is the usual dose of Irsamla?+
The dosage of Irsamla is individualized by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Specific dosing regimens are not provided here and should follow the prescriber’s instructions.
Is Irsamla safe during pregnancy or breastfeeding?+
Safety data for vortioxetine in pregnancy and lactation are limited. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing individuals.
How do I order Irsamla from GNH USA?+
To place an order, submit an enquiry on the product page at gnh-usa.com specifying the required quantity. GNH USA works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.
How does Irsamla compare with other antidepressants?+
Compared with traditional selective serotonin reuptake inhibitors, vortioxetine offers a broader receptor profile, which may provide benefits in cognitive symptoms and a different side‑effect spectrum. Choice of therapy should be guided by clinical response, tolerability, and individual patient factors.
How should Irsamla be stored and handled?+
Store Irsamla at room temperature, below 25 °C, in the original packaging. Protect the tablets from moisture, heat, and direct sunlight to maintain stability.
How is Irsamla administered?+
Irsamla is taken orally, usually once daily, with or without food, as directed by the prescriber. Swallow the tablet whole with water; do not crush or split unless instructed.
What are the most serious risks associated with Irsamla?+
Serious risks include the potential for serotonin syndrome, emergence of suicidal thoughts or behaviors, severe hyponatremia, allergic reactions, and QT interval prolongation. Prompt medical attention is required if any of these occur.
Who should not use Irsamla?+
Irsamla should be avoided in patients with known hypersensitivity to vortioxetine or any excipients, those currently taking MAO inhibitors, or individuals with a history of serotonin syndrome. Clinicians must assess each patient’s medical history before prescribing.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Vortioxetine Hydrobromide
Route
Oral Use
Manufacturer
Egis Pharmaceuticals Plc
Origin
EU

Related products

Brintellix

Brintellix

Vortioxetine Hydrobromide

H. Lundbeck A/S
EU
Brintellix

Brintellix

Vortioxetine Hydrobromide

H. Lundbeck A/S
EU
Brintellix

Brintellix

Vortioxetine Hydrobromide

H. Lundbeck A/S
EU
Irsamla

Irsamla

Vortioxetine Hydrobromide

Egis Pharmaceuticals Plc
EU